Price movement over the last 24 hours
Abeona Therapeutics Inc vs United Airlines Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while United Airlines Holdings Inc trades at $124.07 (market cap $41.65B). The key difference: United Airlines Holdings Inc is far larger — about 111.6× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | UAL | |
|---|---|---|
Market Cap | $373.32M | $41.65B |
Sector | Health | Industrials |
52-Week High | $7.23 | $136.11 |
52-Week Low | $4.17 | $80.18 |
Enterprise Value | $228.22M | $58.45B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
United Airlines (UAL) trades at $128.31, down 3.76% over 24 hours, with a bullish technical signal from moving averages and strong analyst consensus. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.19 surpassing the $1.08 estimate. Financially, UAL shows robust revenue growth, improving profit margins, and attractive valuation ratios, including a P/E of 11.85 and P/S of 0.72. Recent developments include expansion of Starlink Wi-Fi and new routes, supported by positive sector news on lower fuel costs and stable fares.
The outlook for UAL is positive, driven by earnings momentum, cost tailwinds, and strategic growth initiatives. Investment opportunities include upside to the $160.88 consensus price target and sector recovery. Key risks involve fuel price volatility, competitive pressures, and regulatory changes, which could impact profitability and stock performance.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →